ClinicalTrials.gg
CompletedNCT04037657Updated Jul 31, 2019

Evaluating the Safety, Pharmacodynamics and Pharmacokinetics of HSK3486 in Healthy Female Subjects.

A Phase 1 interventional study of HSK3486 and Propofol in Anesthesia and Sedation, sponsored by Sichuan Haisco Pharmaceutical Group Co., Ltd. Completed. Open to female participants aged 18 Years to 49 Years. Per ClinicalTrials.gov, last updated 2019-07-31.

Sponsored by Sichuan Haisco Pharmaceutical Group Co., Ltd (part of Haisco Pharmaceutical Group Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years 2 months after the study started (first participant enrolled Apr 2015, registered Jul 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years to 49 Years
Sex
Female
01

Study summary

This study was a single-center positive-controlled, randomized, dose-escalation study of HSK3486 in healthy female subjects administered as a single IV bolus dose.Subjects were confined to the study unit from the evening of Day -1 until the morning of Day 2, then were required to return for a follow up visit on Day 5. Intensive safety, PD and PK assessments were performed prior to dosing on Day 1 until 24 hours post-dose (Day 2).

02

Conditions studied

  • Anesthesia
  • Sedation
03

In context

Lead sponsor

Sichuan Haisco Pharmaceutical Group Co., Ltd is the lead sponsor of 30 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female, aged 18 - 49 years (inclusive)
  • Women of agreed to use adequate prior to study entry, for the duration of study participation, and for 90 days following completion of therapy
  • Negative serum pregnancy test
  • In general good health without CS medical history
  • (ASA) Physical Status Classification of I or II
  • (BMI) between 18 and 30 kg/m2 (inclusive)
  • Negative screen for drugs of abuse, alcohol, surface antigen (HBs-Ag), virus antibody (HCV-Ab) and (HIV) at screening; and drugs of abuse, alcohol pre dose on Day -1
  • Normal or non-CS findings on a physical examination, 12-lead (ECG) and vital signs (respiratory rate between 12 and 20 breaths per minute, blood pressure (BP) between 100-140/60-90 mmHg, heart rate between 50-99 beats per minute, temperature between 35.8°C and 37.5°C and pulse oximetry values > 95% on room air)
  • Clinical laboratory values within the normal limits as defined by the clinical laboratory, unless the PI decided that out-of-range values were not CS
  • Able to provide written
  • Willing and able to follow study instructions and likely to complete all study requirements
  • Suitable venous and arterial access

Exclusion criteria

Exclusion Criteria:

  • History of allergy or sensitivity to: propofol, components of Fresofol 1% MCT/LCT propofol, or HSK3486 ( soy bean oil, glycerine, triglycerides, purified egg phospholipids, sodium oleate and sodium hydroxide), or plain lignocaine
  • History of CS problems with general anesthesia
  • Current smoker, or a history of regular (more than weekly) use of tobacco- or nicotine-containing products within 2 months prior to screening
  • History of excessive alcohol intake (more than four standard drinks daily, on average) or use of recreational drugs within the last 3 months CONFIDENTIAL HSK3486 SAD_02 Sichuan Haisco Pharmaceutical Co., Ltd Version: 13 Nov 2015 Page 19 of 513
  • Use of prescription or over the counter medications within 7 days of Product administration, with the exception of medications, paracetamol, oral non-steroidal anti-inflammatory agents, topical over the counter preparations and routine vitamins (if they do not exceed an intake of 20 to 600 times the recommended daily dose), unless agreed as non- by the PI and Sponsor.
  • Standard donation of blood within 30 days of the study
  • Donation of plasma or participation in a plasmapheresis program within 7 days preceding this study
  • Receipt of any investigational study drug within 30 days prior to screening
  • Unable to fast for the 6 hours prior to Investigational Product administration
  • CS (as judged by the Investigator) presence of acute illness (e.g. gastrointestinal illness, infection such as influenza, upper respiratory tract infection) at admission to the clinical study unit
  • Anticipated need for surgery or hospitalization during the study
  • Anatomical abnormality that would potentially interfere with airway management under unconscious sedation or anesthesia
  • History of posture-related gastric reflux more than twice weekly
  • History of seizures or epilepsy
  • History of ischaemic heart disease
  • History of brady- or tachy-dysrhythmias requiring medical care
  • History of asthma, with bronchospasm requiring treatment in the last 3 months
  • Any condition, which in the Investigator's opinion, puts the subject at significant risk, could confound the study results or may interfere significantly with the subject's participation in the study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    HSK3486

    0.288 mg/kg ,0.432 mg/kg ,0.540 mg/kg ,0.648 mg/kg,0.810 mg/kg There were five cohorts of six subjects per cohort (5 HSK3486:1 propofol).

    Drug: HSK3486

  • Active comparator
    Propofol

    2.5 mg propofol

    Drug: Propofol

Interventions

  • HSK3486 was administered as a single dose over a 1 minute infusion period. There were five cohorts of six subjects per cohort (5 HSK3486:1 propofol).

  • Propofol, at a dose of 2.5 mg/kg, was administered as a 1 minute infusion at a constant rate via infusion pump.

06

What researchers measure

Primary outcomes

  1. Safety by measurement of Adverse Events

    Time frame: First dose of study drug on day 1

  2. Bispectral index (BIS)

    Time frame: From first dose of study drug until fully alert on day 1

  3. Modified observer's assessment of alertness/sedation(MOAA/S)

    Observe the change of modified observer's assessment of alert /sedation during the whole trial

    Time frame: Time Frame: From first dose of study drug until fully alert on day 1

Secondary outcomes

  1. Median effective dose (ED50)

    Time frame: From first dose of study drug until fully alert on day 1

  2. Peak concentration (Cmax)

    Time frame: From the start of administration to 48 hours after administration

  3. Time to plasma peak concentration(Tmax)

    Time frame: From the start of administration to 48 hours after administration

  4. Area Under the Curve (AUC0-30min, AUC0-1h, AUC0-last, and AUC0-inf)

    Time frame: From the start of administration to 48 hours after administration

  5. Total clearance (CL)

    Time frame: From the start of administration to 48 hours after administration

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2015 to primary completion in Jun 2015, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2019
First posted
Jul 30, 2019
StartActual
Apr 22, 2015
Primary completionActual
Jun 9, 2015
CompletionActual
Nov 13, 2015
Last update
Jul 31, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04037657
Responsible party
Sponsor
First posted
Jul 30, 2019
Start date
Apr 22, 2015
Primary completion
Jun 9, 2015
Completion
Nov 13, 2015
Last update
Jul 31, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ciprofol

Start the discussion